CORPORATE PRESENTATION

39th Annual J.P. Morgan Healthcare Conference

Dan Lang, MD
Senior Director, Corporate Development Athenex, Inc.
President, Axis Therapeutics Limited

January 2021

NASDAQ:ATNX

www.athenex.com

Forward Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward-looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the "Company"), its officers or its management with respect to the consolidated results of operations and financial condition of the Company. These statements can be recognized by the use of words such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "guidance," "intend," "likely," "may," "opportunity," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," or words of similar expressions. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our ability to obtain and maintain regulatory approvals for our product candidates; our reliance on third parties for success in certain areas of Athenex's business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to service our existing and any future debt obligations and comply with financial and restrictive covenants contained in the agreements governing our indebtedness; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; our ability to integrate acquired assets and businesses into our existing operations; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in the Company's public filings with the U.S. Securities and Exchange Commission (the "SEC"), copies of which are available for free in the Investor Relations section of the Company's website at https://ir.athenex.com/financial-information/sec-filings or upon request from the Company's Investor Relations Department. Information about the Company and any forward-looking statements contained in this presentation are provided and made only as of 11 January 2021 and should not be relied upon as predictions of future events. The Company assumes no obligation and does not undertake to revise or update forward-looking statements to reflect future events or circumstances, except as required by law.

DISCLAIMER

This presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities. Neither this presentation nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the Securities Act of 1933, as amended.

Our historical results are not necessarily indicative of results to be expected for any future period. The financial data contained in this presentation for the periods and as of the dates indicated are qualified by reference to and should be read in conjunction with our financial statements and related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our public filings with the SEC.

Global Oncology-Focused Biopharmaceutical Company

Improving the lives of cancer patients everywhere

Late-Stage Oncology Company	• **Oral paclitaxel and encequidar** for metastatic breast cancer: **PDUFA date - Feb. 28, 2021**; **Priority Review granted** • **Klisyri® (tirbanibulin)** for actinic keratosis received FDA approval in Dec. 2020
Orascovery Platform	• Building oral chemotherapy backbone for IO and targeted therapies • Differentiated by safety, efficacy, as well as convenience
Orascovery Opportunity	• Oral Paclitaxel in mBC addresses HR+/HER2- and TNBC • Growth through: (1) label expansion, (2) combo trials, and (3) new indications • **Pipeline growth opportunities expand initial 70,000 addressable patient opportunity to 500,000+ addressable patient opportunity**
Pipeline	• Oral Paclitaxel plus pembrolizumab • TCR-T Immunotherapy (TCRT-NYESO-A2) – multiple tumor types
Vertically Integrated	• Commercial infrastructure in place to support proprietary product launch* • Global clinical development operations
Financials	• Cash runway through 2023

* If approved

Increasing Importance of Oral Chemotherapy Options



JNCCN: Improving COVID-19 Safety for Cancer Patients and Healthcare Providers

PLYMOUTH MEETING, PA [April 9, 2020] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is continuing to share new resources for optimal cancer management amid new and changing challenges related to the Coronavirus Disease 2019 (COVID-19). The nonprofit organization's Best Practices Committee has published a new article online-ahead-of-print in *JNCCN—Journal of the National Comprehensive Cancer Network* detailing their recommendations for keeping cancer patients, caregivers and staff as safe as possible.

The NCCN Best Practices Committee recommendations can be summarized as follows:

Patient Safety

- Prescreen and screen for COVID-19 symptoms and exposure history via telephone calls or digital platforms
- Develop screening clinics to allow for patien
  dedicated unit with dedicated staff
- Convert in-person visits to telemedicine visi
- Limited or no visitor policy
- Limit surgeries and procedures to only esse
- Consideration of alternative dosing schedul
  and/or the infusion center
- Switch from infusional therapy to oral oncol
- Transition outpatient care to care-at-home v
  of growth factors, hormone therapy)
- Increase interval between scans or use bio
- Provide resources for wellness and stress management for patients

- Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center
- Switch from infusional therapy to oral oncolytics if equivalent formulation is available

Source: https://www.nccn.org/about/news/newsinfo.aspx?NewsID=2025

Orascovery Platform: Encequidar, a Novel P-gp Pump Inhibitor

Designed to Enable Oral Absorption of Chemotherapy Agents

CHEMOTHERAPY BIOAVAILABILITY

Many chemotherapies are P-gp substrates, and can only be given intravenously

ENCEQUIDAR

- Selective inhibitor of P-gp
- Minimal systemic bioavailability

ORAL CHEMOTHERAPY + ENCEQUIDAR

Encequidar is designed to allow for oral absorption of chemotherapy agents such as paclitaxel, irinotecan, docetaxel, topotecan and eribulin



POTENTIAL ADVANTAGES OF ENCEQUIDAR[1]

- Minimal systemic absorption
- Localized P-gp inhibitory activity in GI tract
- No significant systemic side effects to other organs & cells seen in clinical studies
- Expect lower incidence of severe toxicities associated with IV chemotherapy agents

[1] Based on research and clinical studies to date

Pharmacokinetic Model of Oral Paclitaxel

P-gp Pump Inhibition Resulted in Higher Drug Exposure and Better Tolerability Than IV

Oral Paclitaxel 205 mg/m^2 QDx3 weekly* vs. IV Paclitaxel 175 mg/m^2 Q3W



* Dosing regimen is 15mg encequidar and 205mg/m^2 oral paclitaxel for 3 consecutive days per week

Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer

Clinical Trial Designed to Support Registration in the U.S.

(Presented at 2019 SABCS)



Primary Endpoint: ORR

- Radiologically confirmed overall response rates at two consecutive timepoints (RECIST v1.1)
- Blinded assessments by 2 independent radiologists, independent adjudicator
- Scans at weeks 10, 16, 19 / 22

Secondary Endpoints: PFS, OS

Population	OPE	IVP
ITT[2] (N=402)	265	137
Safety[3] (N=399)	264	135
Prespecified mITT[4] (N=360)	235	125

[1] Dosing regimen of the oral paclitaxel and encequidar arm is 15mg encequidar and 205mg/m^2 oral paclitaxel for 3 consecutive days per week
[2] Intent-to-treat population includes all randomized subjects
[3] All patients who received ≥1 dose of OPE or IVP
[4] Baseline evaluable scan: patients with metastatic RECIST lesion on central review; all patients who received at least 7 doses of OPE or one dose of IVP

Phase III Study of Oral Paclitaxel Met Primary ORR Endpoint

Statistically Significant Improvement in ORR Compared to IV Paclitaxel

(Presented at 2019 SABCS)

Confirmed Response Rate (ITT Population)



Confirmed Response Rate (Prespecified mITT Population)



ITT, intent-to-treat population (N=402); mITT, modified intent-to-treat population (N=360)

Overall Survival in ITT Population

(Data cut: September 2020)

(Presented at 2020 SABCS)



OS, ITT (N=402)	Median Estimate, mo	Censored Summary, %	Patient deaths (events), %
OPE (n=265)	**22.7**	**42**	**58**
IVP (n=137)	16.5	35	65

OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group; mITT, modified intent-to-treat population; CI, confidence interval; HR, hazard ratio

Progression-Free Survival in ITT Population

Trend in Favor of Oral Paclitaxel (Data cut: September 2020)

(Presented at 2020 SABCS)



PFS, ITT (N=402)	Median Estimate, mo	Censored Summary, %	Patients with event[1], %
OPE (n=265)	**8.4**	**43**	**53**
IVP (n=137)	7.4	30	64

OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group; mITT, modified intent-to-treat population; CI, confidence interval; HR, hazard ratio

[1] Event is defined as radiological disease progression by central review or death collected in eDC within 90 days of the last tumor assessment

Treatment-emergent Adverse Events of Interest (TEAEs)

Safety Population (N=399)

(Presented at 2020 SABCS)

Cumulative Risk of Neuropathy Relevant[1] with CTCAE Grade ≥2



Neuropathy TEAEs (% of population)	OPE (n=264)	IVP (n=135)
Neuropathy relevant[1] with CTCAE grade ≥2	8.0%	31.0%
Neuropathy relevant[1] with CTCAE all grades	22.0%	64.0%

Incidence of Vomiting and Diarrhea (% of Population)	Pre-Amendment (n=75)	Post Amendment (n=189)
Incidence of Vomiting (OPE) grades ≥2	31.0%	11.0%
Incidence of Diarrhea (OPE) grades ≥2	36.0%	19.5%

OPE, Oral Paclitaxel Group; IVP, IV Paclitaxel Group

[1] Includes burning sensation, dysesthesia, hypoesthesia, hyporeflexia, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy

Market Opportunity for Oral Paclitaxel in MBC in the U.S.

Metastatic Breast Cancer Represents 160,000 to 170,000 Patients

HER2+ Incidence Rate: ~14%[1]	HR+/HER2- Incidence Rate: ~68%[1]	TNBC Incidence Rate: ~10%[1]	Unknown Incidence Rate: ~8%[1]	
Common regimens • Herceptin in combination with paclitaxel • Herceptin monotherapy • Kadcyla monotherapy • Perjeta in combination with Herceptin and docetaxel	Endocrine therapy +/- CDK 4 & 6 inhibitor	**Oral Paclitaxel and Encequidar**		1L
	Oral Paclitaxel and Encequidar			2L
	Oral Paclitaxel and Encequidar			3L

Oral Paclitaxel Initial Target Addressable Market of ~70,000 in MBC[2]

[1] National Cancer Institute (SEER 2013-2017)
[2] Estimated target patients that would be eligible for chemotherapy (various sources, Breast Cancer, United States, 2019).
Forecast figures and/or estimates are not guarantees of future performance and involve risks and uncertainties. Actual results might differ materially from the forecast figures and/or estimates

Commercial Preparations on Track

MEDICAL AFFAIRS

- ✓ Established scientific communication platform
- ✓ Key data generation and publication plans in process
- ✓ Initiated health economics studies
- ✓ Hired MSL team, staffed and engaging with thought leaders
- ✓ Hired oncology nurse educator team

MARKET ACCESS

- ✓ Defined trade and distribution strategy
- ✓ Developed payer value proposition
- ✓ Completed pricing and contracting
- ✓ Developed patient support strategies
- ✓ Hired director of payor team
- ✓ Hiring payor account team

MARKETING

- ✓ Launched “Facing MBC Together” campaign
- ✓ Established brand positioning and customer segmentation
- ✓ Identified go-to-market tactical plan
- ✓ Launched HCP unbranded campaign to elevate CIPN

SALES

- ✓ Completed account targeting
- ✓ Building data infrastructure
- ✓ Building CRM platform
- ❑ Target team of 50-55 sales reps
- ❑ Hiring 25 territory reps upon approval to cover 70% of the highest prescribers

Opportunity to Expand Oral Paclitaxel's Addressable Market

Potential Addressable US Patients:

> 545,000 (US Incidence)



Source: New cases in 2020 estimated based on SEER by National Cancer Institute
Note: The graph is for illustrative purpose only. It may not reflect the actual scale and the selected diseases do not represent our comprehensive list of targeted indications
[1] Including laryngeal, oral cavity and pharyngeal cancers

I-SPY 2 Launches New Study Arm with Oral Paclitaxel

In Combination with GSK's dostarlimab (PD-1 Antibody)

Goal of Study: Evaluate the safety and efficacy of Oral Paclitaxel in combination with dostarlimab +/- carboplatin in the neoadjuvant breast cancer setting

Primary Objective: Determine whether this regimen increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy alone in specific biomarker signatures



Klisyri for Actinic Keratosis

Two Phase III Pivotal Studies in the U.S. Completed

- Double-blind, vehicle-controlled, randomized, parallel group, multicenter
- Enrolled 351 subjects in 31 U.S. sites per study (N=702)

Efficacy Results

% of Subjects in ITT population (# of Subjects)	KX01-AK-003			KX01-AK-004		
	Tirbanibulin N=175	**Vehicle N=176**	**p-value**	**Tirbanibulin N=178**	**Vehicle N=173**	**p-value**
100% AK Clearance **(primary endpoint)**	**44%** (N=77)	5% (N=8)	**<0.0001**	**54%** (N=97)	13% (N=22)	**<0.0001**

Safety Results

- **Compliance** to 5-day of self-treatment was **over 99%** for both studies
- **Local skin reactions** were mostly **mild to moderate**
- Treatment-related adverse events were mild to moderate application site symptoms, e.g. pruritus or pain
- No serious adverse events or early discontinuations due to study drug related adverse events

Actinic Keratosis (AK) Market Opportunity Is Significant

Actinic Keratosis Market Opportunity

- Common pre-cancerous skin condition characterized by scaly crusty skin lesions due to over exposure to the sun
- An estimated 10-15% of AK cases progress to cancer if left untreated[1]
- Estimates suggest more than 40 million Americans develop AKs each year.[2]
- AK represents the second most common diagnosis made by dermatologists in the U.S.[3]
- Klisyri is a first-in-class microtubule inhibitor indicated for the treatment of Actinic Keratosis of the face or scalp
- Differentiated clinical and safety profile with a short duration five-day treatment

License agreement with Almirall	
Upfront Fee / Near Term Payments	$55 million
Milestones	$65 million aggregate associated with launch and additional indications Eligible for additional sales milestones
Royalties	Tiered royalties starting at 15% based on annual net sales with incremental increases in royalty rates with increased sales
Territories	U.S. and all of Europe including Russia and Turkey

1. American Osteopathic College of Dermatology. https://www.aocd.org/page/ActinicKeratosis
2. American Academy of Dermatology Association (AAD). https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-overview
3. Wilmer EN, Gustafson CJ, Ahn CS, Davis SA, Feldman SR, Huan WW. Most common dermatologic conditions encountered by dermatologists and non-dermatologists. Cutis. 2014 Dec; 95(6):285-92.

Financial Snapshot

Revenue for the nine-month period ended September 30, 2020	**$122.6 million**
• *Product sales, net*	*$83.5 million*
• *License and other revenue*	*$39.1 million*
Cash, cash equivalents, restricted cash and short-term investments as of September 30, 2020	**$242.1 million**
Potential gross proceeds from the financing agreements with Oaktree and Sagard Healthcare (June and August 2020)	**$275.0 million**
• *Amount drawn down as of September 30, 2020*	*$125.0 million*
• *Term Loan Facility available contingent upon future milestones*	*$100.0 million*
• *RIF Facility available contingent upon future milestones*	*$50.0 million*
Shares outstanding (basic) as of September 30, 2020	**93.3 million**
Shares outstanding (fully diluted) as of September 30, 2020	**106.4 million**

Deep Pipeline of Potentially Transformative Therapies

Athenex's Pipeline (as of Jan. 11, 2021)



[1] Rights in Korea
[2] Sub-licensed in Taiwan, Singapore and Vietnam
[3] Sub-licensed in New Zealand and Australia
[4] Sub-licensed / licensed in Mainland China, Hong Kong and Macao
[5] Licensed in Taiwan
[6] Licensed in Taiwan, Mainland China, Hong Kong, Macau, Singapore and Malaysia
[7] Rights in Mainland China
[8] In collaboration with Quantum Leap Healthcare Collaborative and GSK
[9] The FDA approved Klisyri® (tirbanibulin) for actinic keratosis of the face or scalp in December 2020.

Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes

NASDAQ:ATNX

www.athenex.com